Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

rest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The company has a broad proprietary immunotherapy platform for both passive and active immunization against Alzheimer's disease. Also, Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com, or contact:

Elliot Maza, JD, CPA

President & Chief Financial Officer

Intellect Neurosciences, Inc.

7 West 18th Street, 9th Floor

New York, NY 10011, USA

Tel: 212-448-9300

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward- looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Roka Bioscience, Inc. (NASDAQ: ROKA ), ... for the detection of foodborne pathogens,  today announced that ... America Merrill Lynch 2015 Health Care Conference on May 12 ... at the Wynn, Las Vegas NV. ... be available through the investor relations section of Roka Bioscience,s ...
(Date:5/5/2015)... Plymouth, Mich. (PRWEB) May 05, 2015 ... expanding publishing services to develop custom course materials for ... with annual enrollments as low as 200 students. ... to a broader range of higher education instructors,” said ... around the country, we can do our part to ...
(Date:5/5/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... trading on OTCQB  Marketplace, the market for developmental ... for a continuous public market for trading shares ... quotes and market information on us through ... includes U.S. and international companies in venture stage, ...
(Date:5/5/2015)... 5, 2015 Reprints Desk, Inc., a Research ... access to scientific, technical and medical (STM) content, today ... Association of Southeastern Research Libraries (ASERL) . ... across 11 southeastern states. Founded in 1956, ASERL has ... to address the continually changing needs of its member ...
Breaking Biology Technology:Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4
... , , ... CypHer5 TM is a red-excited, pH-sensitive cyanine dye that is ... is therefore ideally suited for monitoring internalization of cell surface receptors ... <P ,>In the assay, the receptor can ...
... Key words: adenoviral vector ... delivery, , ... can greatly aid secondary screening as well as lead and target ... to express target genes of interest at detectable levels takes time. ...
... , , , ... binding assay • LEADseeker • SPA Imaging Beads, ... are present in high levels in the pituitary and are processed ... hormones, and β-endorphin. The various melanocyte stimulating hormones are known to ...
Cached Biology Technology:The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 2The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 3The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 4The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 5The use of CypHer5 for receptor internalization studies in both a range of GPCRs and a non-GPCR 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC5 receptor binding assay using the LEADseeker Multimodality Imaging System 5
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... not want to live a long and healthy life? A ... from ETH Zurich have demonstrated in roundworms. Vitamin B3 ... the worms, diet caused them to live for about one ... of researchers headed by Michael Ristow, a professor of energy ...
... a new treatment for glioblastoma suggest that researchers may ... aggressive of brain tumours, as well as a potential ... to treatment. Presenting the research to the 2013 ... Wick will say that combining radiotherapy with an anti-cancer ...
... particularly neuroproteins that maintain proper brain function. ... known as "tangle diseases" because they are characterized by ... A team of Australian and American scientists discovered ... inserted into neuroproteins, causing them to misfold and aggregate. ...
Cached Biology News:Niacin, the fountain of youth 2Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 2Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor 3New mechanism for protein misfolding may link to ALS 2
... Alkaline Phosphatase Conjugation ... Fluorescein Isothiocyanate Conjugation R. Phycoerythrin Conjugation ... Alexa Fluor 488 Conjugation Alexa Fluor ... Rpe-Alexa Fluor 750 Conjugation Apc-Alexa ...
Qa-1 (6A8.6F10)...
Human Cell Line Slides...
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
Biology Products: